AUG.22'2002 10:47 #5440 P.006/012

U.S.S.N.: 09/768,155 Filed: January 23, 2001

RESPONSE

antibody fragments immunoreactive with anti-dsDNA antibodies, wherein the antibody fragments prevent the anti-dsDNA antibodies from interfering with protein synthesis.

2. (amended) The method of claim 1 wherein the antibody fragments are derived

from human antibodies.

3. (amended) The method of claim 1 wherein the antibody fragments are

conjugated to a carrier molecule or is a fusion protein.

Please cancel claim 4.

5. (amended) The method of claim 1 wherein the antibody fragment is derived from

an anti-idiotypic antibody immunoreactive with anti-dsDNA antibody.

8. (amended) A therapeutic composition in a pharmaceutically acceptable carrier

for administration to a patient comprising an effective amount of single chain anti-idiotypic

antibody fragments immunoreactive with anti-dsDNA antibodies, wherein the antibody

fragments prevent the anti-dsDNA antibodies from interfering with protein synthesis.

9. (amended) The composition of claim 8 wherein the antibody fragments are

derived from human antibody.

10. (amended) The composition of claim 8 wherein the antibody fragments are

conjugated to a carrier molecule or is a fusion protein.

Please cancel claim 11.

12. (amended) The composition of claim 8 wherein the composition is an antibody

fragment derived from an anti-idiotypic antibody immunoreactive with anti-dsDNA antibody.

2

OMRF 168 CIP CON 078617-00116

ATLI #540717 v1